BioSpace News Archive

BioArctic’s founder, Professor Lars Lannfelt, presented data on the binding properties of the anti-amyloid-beta antibody lecanemab and other anti Aβ antibodies.

ONWARD Medical N.V. announces that it has been accepted into the US FDA’s new Total Product Lifecycle Advisory Program for its brain-computer interface technology.

Ossium Health, an innovative bioengineering company that develops bone marrow-derived cell therapies, announced that it has been named to Forbes’ 6th annual list of America’s Best Startup Employers for 2024.

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced initial meal challenge data from INHALE-3 that was presented by Dr. Irl B. Hirsch at the 17th International Conference on Advanced Technologies and Treatments for Diabetes in Florence on March 8th.

Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma

Apellis Pharmaceuticals, Inc. announced that leading retina specialist Philip Ferrone, M.D., will join the company as Chief Medical Retina Advisor, effective March 18.

Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced that the continued strong sales performance of the antifungal Cresemba® by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces it has met the primary endpoint for its Proof of Concept Phase 2a clinical trial of SENS-401 for residual hearing preservation following cochlear implantation.

Ubiquigent Limited, a drug discovery and development company harnessing novel deubiquitinase modulators as new therapeutics for areas of high unmet medical need, announced an agreement with Nanna Therapeutics.

Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced plans to open a new office in London’s vibrant King’s Cross neighborhood.